PDCD1 and cancer: Monoclonal antibodies such as ipilimumab, durvalumab, and nivolumab target cytotoxic T lymphocytes associated antigen 4 (CTLA-4) and programmed cell death 1 (PD1) and its ligand (PDL1) to increase T-cell activity in cancer treatment [86].